The interplay between inflammasome activation and antifungal host defense

Immunological Reviews

Volumn 265, Issue 1, 2015, Pages 172-180

  van de Veerdonk, Frank L ^a   Joosten, Leo A B ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspergillus; Candida; Caspase 1; Fungal infection; Inflammasome

Indexed keywords

ANTIFUNGAL AGENT; INFLAMMASOME;

ANTIFUNGAL RESISTANCE; CONFORMATIONAL TRANSITION; FUNGAL CELL WALL; FUNGAL COLONIZATION; FUNGAL STRUCTURES; FUNGUS HYPHAE; HOST RESISTANCE; IMMUNOTHERAPY; MACROPHAGE; MONOCYTE; MYCOSIS; NONHUMAN; OLIGOMERIZATION; PATTERN RECOGNITION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH17 CELL; ANIMAL; CELL WALL; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MUCOSAL IMMUNITY; MYCOSES; NEUTROPHIL; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; CELL WALL; HUMANS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; INFLAMMASOMES; MYCOSES; NEUTROPHILS; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84927722417     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12280     Document Type: Review

References (85)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012;4:165rv113.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803; quiz 804-805.
3. Patterson TF, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000;79:250-260.
4. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002;16:875-894, vi.
5. Gudlaugsson O, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-1177.
6. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014;157:1013-1022.
7. Anand PK, Malireddi RK, Kanneganti TD. Role of the nlrp3 inflammasome in microbial infection. Front Microbiol 2011;2:12.
8. Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol 2010;10:688-698.
9. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011;11:275-288.
10. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutterwala FS. Cutting edge: Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome. J Immunol 2009;183:3578-3581.
11. Cheng SC, et al. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol 2011;90:357-366.
12. Beauvais A, Fontaine T, Aimanianda V, Latge JP. Aspergillus cell wall and biofilm. Mycopathologia 2014;178:371-377.
13. Fontaine T, Mouyna I, Hartland RP, Paris S, Latge JP. From the surface to the inner layer of the fungal cell wall. Biochem Soc Trans 1997;25:194-199.
14. Hohl TM, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005;1:e30.
15. Ibrahim-Granet O, et al. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol 2010;10:105.
16. McClary DO, Bowers WD, Miller GR. Ultraviolet microscopy of budding saccharomyces. J Bacteriol 1962;83:276-283.
17. Kozubowski L, Heitman J. Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol Rev 2012;36:78-94.
18. Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev 1996;9:469-488.
19. Gross O, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009;459:433-436.
20. van de Veerdonk FL, et al. The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. Eur J Immunol 2011;41:2260-2268.
21. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997;90:939-949.
22. Said-Sadier N, Padilla E, Langsley G, Ojcius DM. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS ONE 2010;5:e10008.
23. Wellington M, Koselny K, Krysan DJ. Candida albicans morphogenesis is not required for macrophage interleukin 1beta production. MBio 2012;4:e00433-e00412.
24. Latge JP, Beauvais A. Functional duality of the cell wall. Curr Opin Microbiol 2014;20:111-117.
25. Gow NAR, van de Veerdonk FL, Brown AJP, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2012;10:112-122.
26. Netea MG, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and toll-like receptors. J Clin Invest 2006;116:1642-1650.
27. Beauvais A, et al. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol 2007;9:1588-1600.
28. Morelle W, Bernard M, Debeaupuis JP, Buitrago M, Tabouret M, Latge JP. Galactomannoproteins of Aspergillus fumigatus. Eukaryot Cell 2005;4:1308-1316.
29. Aimanianda V, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 2009;460:1117-1121.
30. McFadden DC, Casadevall A. Capsule and melanin synthesis in Cryptococcus neoformans. Med Mycol 2001;39(Suppl 1):19-30.
31. Gates MA, Thorkildson P, Kozel TR. Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol 2004;52:13-24.
32. Lamkanfi M, Malireddi RK, Kanneganti TD. Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem 2009;284:20574-20581.
33. Kumar H, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol 2009;183:8061-8067.
34. Kankkunen P, Teirila L, Rintahaka J, Alenius H, Wolff H, Matikainen S. (1, 3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol 2010;184:6335-6342.
35. Bueter CL, et al. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis. J Biol Chem 2011;286:35447-35455.
36. Lei G, et al. Biofilm from a clinical strain of Cryptococcus neoformans activates the NLRP3 inflammasome. Cell Res 2013;23:965-968.
37. Li H, et al. Human pathogenic fungus Trichophyton schoenleinii activates the NLRP3 inflammasome. Protein Cell 2013;4:529-538.
38. Tavares AH, Magalhaes KG, Almeida RD, Correa R, Burgel PH, Bocca AL. NLRP3 inflammasome activation by Paracoccidioides brasiliensis. PLoS Negl Trop Dis 2013;7:e2595.
39. Guo C, et al. Acapsular Cryptococcus neoformans activates the NLRP3 inflammasome. Microbes Infect 2014;16:845-854.
40. Kistowska M, et al. Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signaling. Exp Dermatol 2014;23:884-889.
41. Mao L, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun 2014;82:882-892.
42. Devillers A, et al. Deficient beta-mannosylation of Candida albicans phospholipomannan affects the proinflammatory response in macrophages. PLoS ONE 2013;8:e84771.
43. Hise AG, et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009;5:487-497.
44. van de Veerdonk FL, Kullberg BJ, van der Meer JWM, Gow NAR, Netea MG. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 2008;11:305-312.
45. Wells CA, et al. The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans. J Immunol 2008;180:7404-7413.
46. Gringhuis SI, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol 2012;13:246-254.
47. Flohe L, Brigelius-Flohe R, Saliou C, Traber MG, Packer L. Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997;22:1115-1126.
48. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004;172:2522-2529.
49. Sadikot RT, et al. p47phox deficiency impairs NF-kappa B activation and host defense in Pseudomonas pneumonia. J Immunol 2004;172:1801-1808.
50. Hutchinson DS, et al. Diphenylene iodonium stimulates glucose uptake in skeletal muscle cells through mitochondrial complex I inhibition and activation of AMP-activated protein kinase. Cell Signal 2007;19:1610-1620.
51. van de Veerdonk FL, et al. Reactive oxygen species-independent activation of the IL-1 beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci USA 2010;107:3030-3033.
52. Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010;116:1570-1573.
53. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-832.
54. Ruland J. Inflammasome: putting the pieces together. Cell 2014;156:1127-1129.
55. Ganesan S, et al. Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1beta production in response to beta-glucans and the fungal pathogen, Candida albicans. J Immunol 2014;193:2519-2530.
56. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012;481:278-286.
57. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-325.
58. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004;117:561-574.
59. Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR inflammasome signaling. Curr Opin Struct Biol 2014;29C:17-25.
60. Man SM, et al. Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc Natl Acad Sci USA 2014;111:7403-7408.
61. Joly S, et al. Cutting edge: Nlrp10 is essential for protective antifungal adaptive immunity against Candida albicans. J Immunol 2012;189:4713-4717.
62. Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006;193:1419-1426.
63. van de Veerdonk FL, Kullberg BJ, Netea MG. Pathogenesis of invasive candidiasis. Curr Opin Crit Care 2010;16:453-459.
64. Mencacci A, et al. Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000;68:5126-5131.
65. Joosten LA, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009;60:3651-3662.
66. Segal BH, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009;47(Suppl 1):S282-S290.
67. de Luca A, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 2014;111:3526-3531.
68. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013;39:1003-1018.
69. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Semin Immunol 2013;25:394-407.
70. Moretti S, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog 2014;10:e1004462.
71. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014-1022.
72. Kisand K, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010;207:299-308.
73. Puel A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291-297.
74. Liu L, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011;208:1635-1648.
75. Puel A, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-68.
76. van de Veerdonk FL, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011;365:54-61.
77. Ma CS, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008;205:1551-1557.
78. Tomalka J, et al. A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans. PLoS Pathog 2011;7:e1002379.
79. Lev-Sagie A, Prus D, Linhares IM, Lavy Y, Ledger WJ, Witkin SS. Polymorphism in a gene coding for the inflammasome component NALP3 and recurrent vulvovaginal candidiasis in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol 2009;200:303 e301-e306.
80. Sainz J, Perez E, Gomez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 2008;28:473-485.
81. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 2012;13:352-357.
82. van de Veerdonk FL, et al. Deficient Candida-specific T-helper 17 response during sepsis. J Infect Dis 2012;206:1798-1802.
83. Giamarellos-Bourboulis EJ, et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care 2011;15:R27.
84. Netea MG, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1 beta in monocytes and macrophages. Blood 2009;113:2324-2335.
85. Delsing CE, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 2014;14:166.